DalsnaFinance › Analyst accuracy › Wolfe Research › VRTX target
Wolfe Research raises Vertex stock price target on CF franchise value
Wolfe Research raised its price target on Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) to $562 from $557 while maintaining an Outperform rating.
A fact about what Wolfe Research published, as reported by Investing.com, not a recommendation from Dalsna Finance; Wolfe Research is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.